证券代码：300636 证券简称：同和药业 公告编号：2025-052 江西同和药业股份有限公司 第四届监事会第六次会议决议公告 1、审议通过了《公司2025年第三季度报告》； 监事会对《公司2025年第三季度报告》发表书面审核意见如下： 经审核，监事会认为董事会编制公司《公司2025年第三季度报告》的 程序符合法律、行政法规和中国证监会的相关规定，报告真实、准确、 完整地反映了公司2025年第三季度的财务状况和经营成果，不存在虚 假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 2、审议通过了《关于修订<公司章程>的议案》； 经审核，监事会认为：公司本次修订《公司章程》符合《公司法》 本公司及监事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 江西同和药业股份有限公司(以下简称"公司")第四届监事会第 六次会议于2025年10月17日以电话、邮件的方式向全体监事发出会议 通知，2025年10月24日在公司会议室召开,本次会议由监事会主席余 绍炯主持，以现场表决方式召开，会议应出席监事3人, 实际到会监 事3人。本 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-051 江西同和药业股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江西同和药业股份有限公司(以下简称"公司")第四届董事会第 六次会议（以下简称"会议"）于2025年10月17日以电话及电子邮件 方式发出会议通知，2025年10月24日以现场结合通讯表决的方式在公 司会议室召开,会议应出席董事9人,实际出席董事9人。本次会议由董 事长庞正伟先生主持，公司监事及高管列席了会议。本次会议的召集、 召开和表决程序符合《中华人民共和国公司法》等有关法律、法规及 《江西同和药业股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，会议合法有效。 二、 董事会会议审议情况 经与会董事认真审议，以记名投票表决方式通过以下决议： 1、审议通过了《公司2025年第三季度报告》； 具体内容详见公司同日披露在中国证监会指定的创业板信息披 露网站巨潮资讯网（http://www.cninfo.com.cn）上的《公司2025 年第三季度报告》 ...

Revenue and Profit - Revenue for Q3 2025 reached ¥208,819,135.87, an increase of 11.14% year-over-year[5] - Net profit attributable to shareholders decreased by 3.84% to ¥25,178,078.47 in Q3 2025[5] - Net profit after deducting non-recurring gains and losses fell by 11.49% to ¥22,601,594.83 for the quarter[5] - Basic earnings per share for Q3 2025 were ¥0.0599, down 4.01% compared to the same period last year[5] - Total operating revenue for the current period reached ¥636,241,288.48, an increase of 11.6% compared to ¥569,933,408.38 in the previous period[18] - Net profit for the current period was ¥83,664,591.04, a decrease of 12.6% from ¥95,736,461.60 in the previous period[20] - Basic and diluted earnings per share decreased to ¥0.1992 from ¥0.2280, reflecting a decline of 12.5%[20] Assets and Liabilities - Total assets as of September 30, 2025, were ¥3,258,351,204.58, a decrease of 1.84% from the end of the previous year[5] - The total assets decreased to ¥3,258,351,204.58 from ¥3,319,551,672.71, a decline of approximately 1.8%[16] - The total liabilities decreased to ¥882,543,399.26 from ¥1,010,803,786.88, a reduction of about 12.7%[16] - The company's fixed assets decreased to ¥1,201,567,362.67 from ¥1,301,979,988.18, reflecting a decline of approximately 7.7%[16] - The company’s long-term borrowings decreased to ¥190,100,762.13 from ¥398,500,000.00, a reduction of approximately 52.3%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥193,181,615.14, an increase of 19.13%[5] - Net cash flow from operating activities increased by 19.13% to approximately ¥193.18 million, mainly due to increased cash receipts from sales and services[10] - Cash inflow from investment activities was ¥467,217,368.12, significantly higher than ¥60,297,427.00 in the previous period[20] - Net cash flow from investing activities increased by 106.86% to approximately ¥31.64 million, primarily due to increased phase investment in the second phase of the factory project[10] - Cash inflow from financing activities totaled $358,014,762.13, while cash outflow was $507,117,084.41, resulting in a net cash flow of -$149,102,322.28[21] - The ending balance of cash and cash equivalents increased to $242,538,343.08, compared to $116,345,276.10 in the previous period[21] - The company’s cash and cash equivalents net increase was $77,126,105.32, contrasting with a decrease of $376,457,099.64 in the previous period[21] Investments and Expenses - The company reported a significant increase of 319.60% in long-term equity investments, totaling ¥13,392,121.50, due to additional investments in joint ventures[9] - Research and development expenses increased to ¥41,033,872.63, up from ¥39,204,527.63, indicating a focus on innovation[18] - The company reported a financial asset impairment loss of ¥31,639,391.53, compared to ¥12,375,041.28 in the previous period, highlighting potential challenges[19] - Other income increased by 84.06% to approximately ¥10.29 million, mainly due to an increase in government subsidies[10] - Other income rose to ¥10,290,433.00 from ¥5,590,954.46, reflecting improved operational efficiency[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,461[11] - The largest shareholder, Pang Zhengwei, holds 14.77% of shares, with 4.11 million shares pledged[11] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Fenglong Industrial Co., Ltd., holding 13.22%[11] - The total number of restricted shares at the end of the period is 52,593,811, a decrease of 1,575,855 from the beginning of the period[12] Operational Developments - The company completed the expansion project in the second factory area, with some workshops starting equipment debugging during the reporting period[13] - The company has initiated a new project in the second factory area, with construction starting in July 2022[13] Inventory and Receivables - The company’s inventory decreased to ¥533,227,327.70 from ¥552,510,646.85, a decrease of about 3.5%[15] - Accounts receivable rose to ¥118,196,418.18 from ¥94,676,422.41, indicating an increase of about 25%[15] Financial Adjustments - The third quarter financial report was not audited, indicating that the figures may be subject to adjustments[22]

Group 1 - The core point of the article is that Tonghe Pharmaceutical has received a patent for a new intermediate related to Resmetirom, which may enhance its product offerings and market position [1] - The company reported that for the first half of 2025, its revenue composition is heavily weighted towards pharmaceutical manufacturing, accounting for 99.51% of total revenue, with other businesses contributing only 0.49% [1] - As of the report date, Tonghe Pharmaceutical has a market capitalization of 3.7 billion yuan [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-050 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的发明专利证书，具体情况如下： 发明名称：一种Resmetirom中间体及其制备方法以及中间体III 的制备方法 江西同和药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 本发明提供一种瑞司美替罗新的中间体化合物及其制备方法，以 及将其用于制备瑞司美替罗关键中间体III的方法，该新中间体化合 物的应用可显著降低瑞司美替罗关键中间体III的生产成本和生产周 期。 上述发明专利的取得不会对公司近期生产经营产生重大影响，但 有利于强化公司自主知识产权技术优势，完善知识产权保护体系，从 而增强公司核心竞争力。 特此公告。 江西同和药业股份有限公司董事会 二〇二五年九月十九日 1/ 1 专利号：ZL 2023 1 1118581.4 专利类型：发明专利 专利申请日：2023.09.01 授权公告日：2025.09.19 专利权人：江西同和药业股份有限公司 本发明涉及公司产品瑞司美替罗 ...

Core Viewpoint - The company, Tonghua Dongbao Pharmaceutical, has received a revised Certificate of Suitability (CEP) for its Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production workshop [1] Group 1 - The revised CEP indicates compliance with European pharmacopoeia standards, which is crucial for market access in Europe [1] - The change in the certificate is a strategic move to enhance production capacity and meet regulatory requirements [1] - The new production facility is expected to support the company's growth in the European market [1]

Core Viewpoint - The company, Tonghe Pharmaceutical, has received an updated Certificate of Suitability (CEP) from the European Medicines Agency for its raw material drug, Ticagrelor, due to the addition of a new production facility, effective from September 12, 2025 [1] Group 1: Company Information - Tonghe Pharmaceutical announced the receipt of the updated CEP for Ticagrelor, a novel selective small-molecule anticoagulant [1] - The updated certificate is a result of the company's expansion with a new production workshop [1] Group 2: Product Details - Ticagrelor is designed to block platelet activation, used for treating acute coronary syndrome patients, and aims to reduce the occurrence of thrombotic cardiovascular diseases [1] - The drug is characterized by its rapid and potent effects [1]

Group 1 - The company, Tonghe Pharmaceutical (300636.SZ), has received a revised Certificate of Suitability (CEP) for the raw material drug Ticagrelor from the European Directorate for the Quality of Medicines (EDQM) [1] - The revision is due to the addition of a new production workshop, and the certification scope includes Ticagrelor raw material [1] - The revised certificate will be effective from September 12, 2025 [1]

Core Viewpoint - The company has received a revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production facility [1]. Group 1 - The company announced the receipt of the updated CEP for Ticagrelor active pharmaceutical ingredient [1]. - The revision of the CEP is primarily due to the establishment of a new production workshop [1]. - The effective date for the revised certificate is set for September 12, 2025 [1].

格隆汇9月16日丨同和药业(300636.SZ)公布，近日收到欧洲药品质量管理局（EDQM）颁发的变更后的 替格瑞洛原料药欧洲药典适应性证书(CEP)，本次变更主要原因为公司新增生产车间，变更后的证书自 2025年9月12日起生效。替格瑞洛是一种新型、具有选择性的小分子抗凝血药，可以阻断血小板活化， 用于治疗急性冠脉综合征患者，减少血栓性心血管疾病的发生，具有快速、强效的特点。公司替格瑞洛 产品新增生产车间获得EDQM批准，标志着公司替格瑞洛原料药在欧洲市场的供应能力进一步提升，将 对公司维持和扩大国际市场业务起到积极作用。 ...